Fiche du document
2012
- doi: 10.1038/nature11327
- issn: 0028-0836
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/nature11327
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/22832581
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1476-4687
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_BA87C09DF1FC4
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Therapy Treatments for diseases Medical treatment Therapy Treatment of diseasesCiter ce document
P.A. Northcott et al., « Subgroup-specific structural variation across 1,000 medulloblastoma genomes. », Serveur académique Lausannois, ID : 10.1038/nature11327
Métriques
Partage / Export
Résumé
Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas. SCNAs are common in medulloblastoma, and are predominantly subgroup-enriched. The most common region of focal copy number gain is a tandem duplication of SNCAIP, a gene associated with Parkinson's disease, which is exquisitely restricted to Group 4α. Recurrent translocations of PVT1, including PVT1-MYC and PVT1-NDRG1, that arise through chromothripsis are restricted to Group 3. Numerous targetable SCNAs, including recurrent events targeting TGF-β signalling in Group 3, and NF-κB signalling in Group 4, suggest future avenues for rational, targeted therapy.